A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled, Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2017
At a glance
- Drugs Toreforant (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 08 Jul 2016 Status changed from recruiting to completed.
- 07 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.
- 23 Dec 2015 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.